AXL and non-small cell lung carcinoma: AXL overexpression and activation also conferred resistance to EGFR antibody cetuximab in NSCLC models both in vitro and in vivo and AXL knockdown decreased EGFR phosphorylation in a cetuximab-resistant NSCLC cell line derivative, but not in parental cells [72].